|
Researchers are coaxing the eye to become a biofactory to make its own anti-VEGF medications. This month's feature provides an overview of the leading AAV-based contenders.
Don't miss the EyeNet Corporate Lunches on Saturday, Sunday, and Monday.
Advertisement
Put your patients on the path toward helping to manage their vision
© 2022, Regeneron Pharmaceuticals, Inc. All rights reserved.
|
OPH.22.07.0012
|
|
Publications for This Year's AAO
Ophthalmic Pearls
Clinical Update
Morning Rounds
Blink
Journal Highlights
News in Review
Academy Notebook
Destination AAO
Practice Perfect
Savvy Coder
Opinion
Letters